Loading stock data…
FDMT
$9.23+0.59 (+6.83%)
Market ClosedLast close Jun 9
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
4D Molecular Therapeutics, Inc. in the Healthcare sector is trading at $9.23. Wall Street consensus targets $28.22 (9 analysts), implying a +205.8% move over the next 12 months. The stock is currently 25% below its 52-week high of $12.34, remaining 0.9% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +205.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$9.23
Potential Downside
0%
Whystock Fair Value$9.23
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Buy
Mean target$28.22+205.8%
Range$17.00 – $36.00
Fundamentals
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.61%
Volume
Today's trading volume
601,931
Recent News
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You?
4D Molecular Therapeutics Inc (NASDAQ:FDMT) is one of the best gene therapy stocks to buy in 2026. The stock has gained nearly 30% year-to-date and surged more than 190% over the past year. Looking ahead, analysts expect FDMT stock to almost triple in the next 12 months as the company continues to advance its clinical […]
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy
4D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage development for wet age-related macular degeneration and prepares to begin a Phase 3 trial in diabetic m
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Investors in 4D Molecular Therapeutics, Inc. ( NASDAQ:FDMT ) had a good week, as its shares rose 7.4% to close at...
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -4.12% and -19.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of +7.24% and +46.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?